InvestorsHub Logo

ForReal

11/28/14 2:39 AM

#24641 RE: Empirica #24639

Thank you for your post and clarification.

Hope you will bring a refreshing change and success to the company and shareholders.

TEXASOIL

11/28/14 3:10 PM

#24649 RE: Empirica #24639

The SEC filing actually states you were part of the management team and nothing about an investment group. That is how I read it. Please see below form the SEC Filing.

Shanghai, China – February 17, 2009 – The Board of Directors of Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTCBB: SOBM) is pleased to announce the appointment of a new executive management team to accelerate the Company’s growth.




The new management team members are:



Dr. Anchie Kuo , incoming President and Chief Executive Officer who expects to join the Board of Directors in the future. Dr. Kuo has 20 years of management experience in biotechnology and healthcare firms, most recently as CEO of ARC Medical. He was a founder and managing director of Bank America Venture Partners (now Scale Partners), a $600 million private equity firm and Genaissance Healthcare Fund, a healthcare focused hedge fund, where he focused on investments in the healthcare sector including biopharmaceuticals.


Lionel Choong , recently appointed Chief Financial Officer who expects to also join the Board of Directors in the near future. A former partner with Deloitte Touche Tohmatsu, Mr. Choong has 20 years of experience in corporate finance, business development, IPO and M&A, and financial management and reporting in a variety of industries in Hong Kong, China and overseas, most recently as head of corporate finance of Kennic L.H. Lui & Co, a CPA firm in Hong Kong.

Brent Suen , Head of Strategic Development and Mergers and Acquisitions. Mr. Suen has more than 20 years of experience in the investment industry, both as an investor and an operator of companies, most recently as Executive Director of IRG, where he oversaw deal sourcing and execution for the advisory business for the IRG TMT Asia Fund, primarily in Technology and Life Science companies.


Christopher Metcalf, incoming Chairman of the Board . Mr. Metcalf is an executive with extensive private equity and investment banking experience and has previously held investment positions at Morgan Stanley and GF Private Equity Group.

liable

07/07/15 12:37 PM

#35206 RE: Empirica #24639

I still dare you to come out with an update on one of your fraudulent deals announced in May.